Success Metrics

Active Trials
4(50%)

Phase Distribution

Ph phase_1
2
25%
Ph phase_2
4
50%
Ph phase_3
1
13%

Phase Distribution

2

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
4(57.1%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

8

all time

Status Distribution
Active(5)
Other(3)

Detailed Status

Recruiting4
unknown3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
4
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 24 (57.1%)
Phase 31 (14.3%)

Trials by Status

not_yet_recruiting113%
recruiting450%
unknown338%

Recent Activity

4 active trials
Showing 5 of 8
recruitingphase_3

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

NCT06997497
recruitingphase_2

HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

NCT06860490
recruiting

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

NCT07147101
recruitingphase_1

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

NCT06530251
not_yet_recruitingphase_2

Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）

NCT07007767
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT06997497Phase 3

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Recruiting
NCT06860490Phase 2

HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

Recruiting
NCT07147101

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Recruiting
NCT06530251Phase 1

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

Recruiting
NCT07007767Phase 2

Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）

Not Yet Recruiting
NCT05386524Phase 2

Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC

Unknown
NCT05029973Phase 2

HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC

Unknown
NCT04843943Phase 1

Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC

Unknown

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8